TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total Narcotic Consumption in the Post Anesthesia Care Unit (PACU)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to Discharge Following Surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of participants with Early-Rebleed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with Rebleed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Early-Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Overall score of QLQ-C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety of recombinant interleukin-7 (IL-7)
Endpoint domain: Adverse events/effects
Primary endpoint: Difference between the values of the forced vital capacity (FVC) measured before and after work shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference between the values of the forced expiratory volume in one second (FEV1) measured before and after work shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Acute respiratory symptoms through self-administered questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of all adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Intracellular Glutathione Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fetal aneuploidy detection accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Development of Hypertensive Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum concentration (Cmax) for BMS-986165 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC(0-T)) for BMS-986165 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve extrapolated to infinity (AUC(INF)) for BMS-986165 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygenation change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of metal scatter on CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum platelet aggregation intensity (MAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants with Immune-Related Hepatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Painful response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti Xa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Effective Regurgitant Orifice (ERO) in cm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Patients Achieving IGA of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Bacterial Meningitis
Endpoint domain: Mortality/survival
Primary endpoint: Shoulder Pain and Disability Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms & signs of infection and immune response
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in balance score (SOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total lung ultrasound B-line score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total venous malformation lesion load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Preliminary Satisfactory Response Indicating Disease Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With CR or CRi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With CR, CRi or PR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: pain relief (>50% pain reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Dose-limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Treatment-emergent Adverse Event Leading to Dose Interruption or Reduction
Endpoint domain: Adverse events/effects
Primary endpoint: TNSc score variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour urine aldosterone to creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cardiovascular disease or death
Endpoint domain: Mortality/survival
Primary endpoint: Change in Abbreviated Profile of Hearing Aid Benefit (APHAB)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Suicidal Ideation Questionnaire (SIQ)
Endpoint domain: Adverse events/effects
Primary endpoint: Suicide Attempt and Self-Injury Count (SASI-Count)
Endpoint domain: Adverse events/effects
Primary endpoint: Suicide-related hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: highest grade of oral mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in MERTK signalling cascade on monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in MERTK signalling cascade on tissue macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of tumor clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients retained in care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 3 Hours Plasma Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 3 Hours Plasma Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucagon-like peptide-1 (GLP-1) release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: implant stability quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant position accuracy using cone beam computed tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bone density around implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of recommended actions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of sections of the Facing Forward manual read with satisfaction and comprehension
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving SALT ≤ 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Induction of ketosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: General metabolic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immunological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Retained in Care With HIV Viral Suppression <40 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Retained in Care With Functional Adherence to PrEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration of Digoxin (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve of Furosemide From 0 to Last Quantifiable Data Point (AUC 0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration of Furosemide (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve of Metformin From 0 to Last Quantifiable Data Point (AUC 0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Ongoing Pregnancy Rate
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness of electrochemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rate to gemcitabine hydrochloride and cisplatin with versus without veliparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of single-agent veliparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects not hospitalized or free of respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Any unlocked guns in home
Endpoint domain: Adverse events/effects
Primary endpoint: Any loaded guns in home
Endpoint domain: Adverse events/effects
Primary endpoint: Any unlocked ammunition
Endpoint domain: Adverse events/effects
Primary endpoint: Total Symptom Severity (TSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete histologic polyp eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Central subfield macular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment-related events
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiac repolarisation (QT/QTc interval)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage Change in Spot Urinary Oxalate:Creatinine Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Shoulder Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total SOFA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in Glucose 5-Hour Incremental AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of YM178
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (area under the curve) of YM178 plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum uremic toxins levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients treated with Noroxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Neutrophil Gelatinase Associated lipocalcin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence of food allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficiency in performing nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: maternal-infant interaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Genetic mutations or altered growth factor expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Free From Headache Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythrocyte Salt Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of histological examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative ocular deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skeletal muscle gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skeletal muscle expression before and after ERT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with genetic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported physical activity frequency and duration
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Dating Violence Perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Dating Violence Victimization
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of C. difficile-associated diarrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in diet quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of MPC therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of QFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target vessel failure
Endpoint domain: Adverse events/effects
Primary endpoint: Progress Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Safety of Fluzone vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Preoperative Chronic Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endothelial venodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: frequency of mouth pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of mouth pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of mouth pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End tidal carbon dioxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autonomic Modulation - SD1 index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autonomic Modulation - SD2 index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Response Rate (CRR) at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of check-ins with epinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement of VAS values of global well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Grade 1-2 Treatment-Related AE Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in CD8+ T Cells in Peripheral Blood and Tumor Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Knee extensor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of symptom distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Uptake of Service
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Helped me Stay Healthy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Helped me Make Decisions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: PACIC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MTBQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attendance in outpatient clinics
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient-reported Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Visual Analog Scale for Anxiety (VAS-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analog Scale for Pain (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting 1 or More Unsolicited Non-Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Serum K+ Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: health behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: health utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Therapeutic Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of mammillary fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of device malfunctions
Endpoint domain: Adverse events/effects
Primary endpoint: Retention of single denture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac strain rate imaging (SRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ejection fraction measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood markers (troponin-I and BNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic accuracy of confocal laser scanning microscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: THC and CBD metabolite levels in maternal neonatal blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: THC and CBD metabolite level in umbilical cord blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: THC and CBD metabolite levels in neonatal blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant motor, cognitive, and social development at 6 months of age using the Ages and Stages Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Infant motor, cognitive, and social development at 12 months of age using the Ages and Stages Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Safety labs
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Fospropofol (AUC(0-inf))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Drug Plasma Concentration (Cmax) of Fospropofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Drug Plasma Concentration of Propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC[0-infinity]) of ridaforolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of ridaforolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of a Single Oral Dose of Ridaforolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Half-life (t1/2) of a Single Oral Dose of Ridaforolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With Study Success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Craving Score During Cue Exposure Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Latency to Smoke During Cue Exposure Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Smoke Intake During Cue Exposure Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival without ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Ventilator free survival
Endpoint domain: Mortality/survival